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Abstract
Background: We aimed to investigate the clinical correlates of principal components (PCs) of tau positron emission
tomography (PET) and their predictability for longitudinal changes in tau accumulation in Alzheimer’s disease (AD).
Methods: We enrolled 272 participants who underwent two PET scans [18F-flortaucipir for tau and 18F-florbetaben
for amyloid-β (Aβ)], brain magnetic resonance imaging, and neuropsychological tests as baseline assessments.
Among them, 187 participants underwent the same follow-up assessments after an average of 2 years. Using Aβ-
positive AD dementia-specific PCs obtained from the baseline scans of 56 Aβ-positive patients with AD dementia,
we determined the expression of the first two PCs (PC1 and PC2) in all participants. We assessed the correlation of
PC expression with baseline clinical characteristics and tau accumulation rates. Moreover, we investigated the
predictability of PCs for the longitudinal tau accumulation in training and test sets.
Results: PC1 corresponded to the tau distribution pattern in AD, while the two PC2 extremes reflected the parietal
or temporal predominance of tau distribution. PC1 expression increased with tau burden and decreased with
cognitive impairment, while PC2 expression decreased with advanced age and visuospatial and attention function
deterioration. The tau accumulation rate was positively correlated with PC1 expression (greater tau burden) and
negatively correlated with PC2 expression (temporal predominance). A regression model using both PCs could
predict longitudinal changes in the tau burden (intraclass correlation coefficient = 0.775, R2 = 0.456 in test set).
Conclusions: PC analysis of tau PET could be useful for evaluating disease progression, characterizing the tau
distribution pattern, and predicting longitudinal tau accumulation.
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Background
The recent development of tau-selective positron emission
tomography (PET) radiotracers has facilitated research on
neurodegenerative diseases [1]. 18F-flortaucipir, which is
the most widely investigated radiotracer, selectively binds
to abnormally hyperphosphorylated tau protein in post-
mortem tissue [2]; therefore, it enables in vivo
visualization of tau pathology in Alzheimer’s disease (AD)
[3, 4]. Patients with AD present with increased 18F-flortau-
cipir binding in the medial temporal cortex and associ-
ation neocortices with relative sparing of the primary
sensorimotor and visual cortices [4, 5]. Cortical 18F-flor-
taucipir binding is correlated with the degree of cortical
atrophy and cognitive impairment degree [4, 5] and mir-
rors the pathological stage of AD [3]. Moreover, longitu-
dinal changes in cortical uptake are reflective of the
clinical progression [6]. Therefore, 18F-flortaucipir could
be a surrogate biomarker for the progression of AD.
Principal component analysis (PCA) is a data-driven
method for establishing patterns that explain variance by
reducing the high dimensionality of image data [7]. This
method has been used to identify the specific metabolic
and amyloid-β (Aβ) accumulation patterns for AD and
healthy aging [7–10]. Using PCA, we aimed to identify
principal components (PCs) of 18F-flortaucipir PET in
AD dementia. Thereby, we sought to find their clinical
correlates and to investigate the predictability for the
longitudinal changes in tau accumulation.
Materials and methods
Participants
From January 2015 to August 2017, we enrolled 176 pa-
tients at the Memory Disorder Clinic in Gangnam Sever-
ance Hospital and 96 healthy controls. We first enrolled
patients with amnestic-type dementia with a probable
AD diagnosis according to the National Institute of
Neurological and Communicative Disorders and Stroke
and the Alzheimer Disease and Related Disorders Asso-
ciation [11], as well as patients with a mild cognitive im-
pairment (MCI) diagnosis according to Petersen’s
criteria. The patients with AD dementia first presented
with amnesia and did not present clinical features atyp-
ical for AD, including posterior cortical atrophy, logope-
nic aphasia, or frontal-variant AD. The healthy controls
met the Christensen’s diagnostic criteria and underwent
similar clinical and neuroimaging assessments [12]. The
healthy controls presented normal cognition based on
the neuropsychological test battery, no previous history
of head trauma and neurological/psychiatric illness, and
no brain magnetic resonance (MR) imaging abnormality
except for the mild to moderate degree of white matter
hyperintensities. For baseline assessments, all the partici-
pants underwent a clinical interview, neuropsychological
test battery, genotyping for ApoE, and brain MR
imaging, as well as 18F-flortaucipir and 18F-florbetaben
PET imaging. Among the 272 participants, 187 partici-
pants underwent similar follow-up neuropsychological
and neuroimaging assessments after a mean duration of
2.0 ± 0.3 years.
Standard protocol approvals, registrations, and patient
consent
This study was approved by the institutional review
board of Gangnam Severance Hospital. We obtained
written informed consent from all the participants. All
procedures performed in this study were in accordance
with the ethical standards of the 1964 Helsinki declar-
ation and its later amendments.
Neuropsychological tests
All the participants underwent the Seoul Neuropsycho-
logical Screening Battery (SNSB) [13]. Cognitive domain
functions were measured using the scorable items as
proposed by the SNSB developers [14]. To assess global
cognitive function, we measured the mini-mental state
examination scores, clinical dementia rating sum-of-
boxes (CDR-SB) scores, and composite scores for five
cognitive domains [14].
Acquisition of PET and MR images
We performed 18F-flortaucipir and 18F-florbetaben PET
on separate days. We acquired PET images using a Bio-
graph mCT PET/CT scanner (Siemens Medical Solu-
tions, Malvern, PA, USA) for 20 min at 80 and 90 min
after 18F-flortaucipir and 18F-florbetaben injections, re-
spectively. We reconstructed 3D PET images in 256 ×
256 × 223 matrices with 1.591 × 1.591 × 1mm voxel size
using the ordered-subsets expectation-maximization al-
gorithm after attenuation correction. Aβ-positivity was
determined after agreement of two nuclear medicine
specialists after visual assessment [15, 16]. T1-weighted
brain MR images were acquired using a 3.0 Tesla MR
scanner (Discovery MR750, GE Medical Systems,
Milwaukee, WI) with 3D spoiled gradient-recalled se-
quences (repetition time = 8.28 ms, echo time = 1.6 to
11.0 ms, flip angle = 20°, 512 × 512 matrix, voxel spa-
cing = 0.43 × 0.43 × 1mm).
Image processing steps
First, MR images were processed using FreeSurfer 5.3
(Massachusetts General Hospital, Harvard Medical
School; http://surfer.nmr.mgh.harvard.edu) to obtain
participant-specific volume-of-interest (VOI) images
with the subcortical and cortical regions labeled as previ-
ously described [3]. PET images were co-registered to
individual MR images within the FreeSurfer space
(256 × 256 × 256 matrix with 1 mm isovoxels) and then
corrected for partial volume effect (PVE) using regional
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mask images based on the region-based voxel-wise
method [17]. Subsequently, we converted PVE-corrected
PET images to standardized uptake value ratio (SUVR)
images with the cerebellar crus median as a reference.
We measured regional SUVR values by overlaying
participant-specific VOI images on the obtained PVE-
corrected PET images.
We used statistical parametric mapping 12 (SPM12,
Wellcome Trust Centre for Neuroimaging, London, UK)
and in-house software implemented in MATLAB 2015b
(MathWorks, Natick, MA, USA) for spatial normalization
and PCA. We spatially normalized inhomogeneity-
corrected MR images to the in-house diffeomorphic ana-
tomical registration using exponentiated lie algebra
(DARTEL) template in 181 × 217 × 181 matrices with 1
mm isovoxels using the DARTEL toolbox in SPM12 [18].
Subsequently, we normalized the PVE-corrected SUVR
images by applying flow fields normalizing gray and white
matter. Finally, spatially normalized SUVR images were
smoothed in a 3D space using a Gaussian kernel with 8
mm full-width half-maximum followed by PCA
performance.
Principal component analysis
For PCA, we used in-house software implemented in
MATLAB, as previously described [8]. For all the partici-
pants, SUVR values of the gray matter voxels in the in-
house atlas were first transferred to a row vector with
628,181 elements after demeaning the values [19]. To
obtain Aβ-positive AD dementia-specific PCs, we cre-
ated an M ×N data matrix (M = number of patients, N =
number of vector elements) using the 56 Aβ-positive pa-
tients with AD dementia. The data matrix was decom-
posed into three matrices through singular value
decomposition; subsequently, we obtained an M ×N
matrix for Aβ-positive AD dementia-specific PCs. We
converted row vectors for each PC into 3D volumes for
visualization. Using these Aβ-positive AD dementia-
specific PCs as a reference, we calculated the estimated
component weights reflecting the expression of each ref-
erence PC in each gray matter voxel in all participants.
Based on the PC1 and PC2 expression, we classified 114
Aβ-positive individuals into quartile groups.
Statistical analysis
All statistical analyses were performed using SPSS 23
(IBM Corp., Armonk, NY, USA). Between-group com-
parisons of demographic data were performed using the
one-way ANOVA test or independent t test for continu-
ous variables and the chi-square test for categorical vari-
ables. We used Pearson’s correlation analysis to
determine the correlation of PC expression with age and
global cortical SUVR. Moreover, we used partial correl-
ation analysis to determine the correlation between PC
expression and cognitive functions with adjustments for
age, years of education, sex, and the presence of ApoE
ε4 allele. Partial correlation analysis was performed in
two stages: the first involved a calculation of the stan-
dardized residuals of the linear regression analysis with
the demographic data as independent variables, and the
second involved Pearson’s correlation analysis between
the standardized residuals for the two variables of inter-
est. To investigate the association between PC expres-
sion and longitudinal tau accumulation, we first
compared annual changes in the SUVR values between
the quartile groups for PC1 and PC2 expression by using
the general linear model with adjustments for age, years
of education, sex, presence of ApoE ε4 allele, and base-
line global cortical SUVR values. We used Bonferroni’s
method to correct for multiple comparisons. Second, we
performed partial correlation analysis between PC ex-
pression and annual changes in the SUVR values after
adjusting for the same covariates. Regarding prediction
of longitudinal changes in tau accumulation, we con-
ducted linear regression analysis with the annual
changes measured by the two tau PET studies as the
dependent variables and PC1 expression/PC1 and PC2
expression, age, years of education, sex, and presence of
ApoE ε4 allele as independent variables. To validate this
model, we first divided the samples into two equal
groups based on the date of the baseline scan. One
group served as a training set to obtain the parameters
Table 1 Demographic characteristics of the study participants
CU MCI DEM
n 96 105 71
Age (years) 66.3 ± 9.5 71.1 ± 9.1a 74.4 ± 9.3a
Sex (M to F) 36: 60 41: 64 17: 54
Education (years) 11.9 ± 4.5 11.2 ± 4.5 9.8 ± 5.7a
Duration (years) n.a. 2.3 ± 1.3 3.5 ± 1.5b
ApoE ε4 genotype 17/96 (18%) 30/105 (29%) 30/71 (42%)a
Amyloid positivity 9/96 (9%) 49/105 (47%)a 56/71 (79%)ab
MMSE 28.2 ± 1.8 25.7 ± 2.7a 19.1 ± 5.3ab
CDR-SB 0 1.5 ± 1.0a 5.0 ± 2.5ab
Total cognition score 183.2 ± 33.8 135.2 ± 33.6a 86.4 ± 34.7ab
Memory 73.3 ± 20.6 44.1 ± 17.9a 23.6 ± 13.9ab
Language 23.8 ± 3.1 20.5 ± 4.2a 16.2 ± 5.6ab
Visuospatial 33.1 ± 4.7 29.6 ± 7.2a 21.0 ± 11.5ab
Frontal/executive 42.1 ± 9.2 31.5 ± 10.3a 17.8 ± 9.3ab
Attention 10.9 ± 2.5 9.6 ± 2.7a 8.1 ± 2.6ab
Abbreviations: CU cognitively unimpaired, DEM Alzheimer type dementia, MCI
mild cognitive impairment, ApoE apolipoprotein E, MMSE Mini-Mental State
Examination, CDR-SB Clinical Dementia Rating sum-of-boxes, n.a.
not applicable
aP < 0.05 for the comparison with CU
bP < 0.05 for the comparison with MCI
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for the regression equation, while the other group was
used to calculate the predicted annual changes.
Data availability statement
The data that support the findings of this study are avail-
able on request from the corresponding author. The data
are not publicly available due to privacy restrictions.
Results
Demographic characteristics
Table 1 summarizes the demographic characteristics. Pa-
tients with AD dementia and MCI were older than
healthy controls. Patients with AD dementia were less
educated and more frequently presented the ApoE ε4 al-
lele compared to the controls; moreover, they had longer
disease duration than patients with MCI. There were
significant between-group differences in the Aβ-
positivity and test performances for global cognition and
five cognitive domains.
Principal components and baseline characteristics
The Aβ-positive AD dementia-specific PC1 pattern was
very similar to the tau distribution and spreading pattern
reported by previous postmortem and tau PET studies
(Fig. 1a) [3–5, 20]. Group-wise averaged 18F-flortaucipir
PET images for each PC1 score quartile in the 114 Aβ-
positive individuals showed an increasing trend of cor-
tical uptake in the more widespread cortex. Moreover,
Aβ-positive AD dementia-specific PC2 showed two ex-
treme 18F-flortaucipir uptake patterns, i.e., temporal and
parietal predominance, which were reflected by the aver-
aged images of the first and fourth quartile groups for
PC2 expression in the 114 Aβ-positive individuals
(Fig. 1b). PVE-uncorrected data also showed similar PC
patterns (Additional file 1: Fig. S2).
The first two Aβ-positive AD dementia-specific PCs
explained 55% of the variances (PC1 = 44% and PC2 =
11%; Fig. 2a). There was a correlation between the ex-
pression of two PCs (P = 0.001, R = 0.200); however,
there was a diverging trend of PC2 scores in individuals
with higher PC1 scores (Fig. 2b). The global cortical
Fig. 1 Voxel-wise maps for Aβ-positive AD dementia-specific PCs of tau PET and group-wise averaged tau PET images for each quartile of PC
scores in 114 Aβ-positive individuals. Individual PC1 scores correlated with the tau uptake in the entire cortex and there was an increasing trend
of cortical tau burden with the advancement of the PC1 quartile groups. Individual PC2 scores correlated with the tau uptake in the prefrontal,
parietal, occipital, and posterior cingulate cortices. The lowest PC2 quartile group (Q1) showed a temporal predominance pattern while the
highest PC2 quartile group (Q4) showed a parietal predominance pattern. Significance maps for the voxel-wise correlation analysis between the
individual scores for the PCs and tau uptake are overlaid on the template. Only the voxels that survived after correcting for multiple comparisons
with family-wise error (P < 0.05) are displayed. Color bars represent PCs (bidirectional cold and hot colors), −Log10P (rainbow color) and SUVR
(rainbow color). PC, principal component; AD, Alzheimer’s disease; SUVR, standardized uptake value ratio; Qn, quartiles
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SUVR values were correlated with both PC1 and PC2
scores; however, the correlation was much stronger with
PC1 scores than with PC2 scores as expected, given the
Aβ-positive AD dementia-specific PC patterns (Fig. 2c,
d). Moreover, there was a correlation between the PC1
scores and global cortical SUVR values even in the Aβ-
negative individuals (P < 0.001, R = 0.412). When we
compared the regional SUVR values of the first and
fourth quartile groups of PC2 expression, the fourth
quartile group showed greater 18F-flortaucipir SUVR
values in the sensorimotor, superior and inferior parietal,
and precuneus cortices. Contrastingly, the first quartile
group showed greater 18F-flortaucipir SUVR values in
the entorhinal cortex and hippocampus (Additional file
1: Table S1).
Both PC1 and PC2 scores decreased with advancing
age; however, aging was better reflected by the PC2
score (Fig. 3a, d). Both PC scores decreased with cogni-
tion worsening except for the PC2 score with CDR-SB
(Additional file 1: Table S2). There was a generally
stronger correlation with PC1 than with PC2 scores;
however, the visuospatial function showed strongest cor-
relation with the PC2 scores (Fig. 3 and Additional file
1: Table S2). PVE-uncorrected data showed similar PC
patterns (Additional file 1: Fig. S2) and results (Add-
itional file 1: Fig. S3 and S4).
Fig. 2 Expression of Aβ-positive AD dementia-specific PCs and global cortical tau burden. a The percentages of variance explained by the first 10
PCs (red bars) and their cumulative percentages (light blue bars). The first two PCs (PC1 and PC2) contributed to 44% and 11% of total variance,
respectively. b Scatter plot of individual scores for PC1 and PC2 expression exhibited divergence of PC2 scores with increased PC1 scores. c PC1
scores clearly reflect the cortical tau burden measured by global cortical SUVR. d PC2 scores were likely to increase with the global cortical SUVR;
however, there was a divergence of PC2 scores among individuals with a higher tau burden. The colors of the circles represent individual clinical
status (blue = CU, green = MCI, and red = dementia), and the closed and open circles represent Aβ-positive and Aβ-negative individuals,
respectively. Pearson’s correlation lines (solid), 95% confidence interval lines (dotted), correlation coefficients (R), and P values are presented in
green color (all 272 individuals) or red color (114 Aβ-positive individuals). PC, principal component; AD, Alzheimer’s disease; MCI, mild cognitive
impairment; CU, cognitively unimpaired
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We also tested above two different reference sets. Even
with the different sets of reference group (114 Aβ-
positive participants and 49 Aβ-positive MCI patients),
there was no clear difference between the patterns of
PCs obtained with the different reference sets (Add-
itional file 1: Fig. S5, S6, S7, and S8). However, the refer-
ence set with 56 Aβ-positive AD dementia was best for
reflecting global cortical tau burden and global
cognition.
Principal components and tau accumulation rate
Among 78 Aβ-positive individuals who underwent
follow-up tau PET assessments, annual changes in the
SUVR values showed an increase tendency in the base-
line PC1 quartile groups and decrease tendency in the
baseline PC2 quartile groups (Fig. 4a, b). In the entorhi-
nal cortex, the annual change in SUVR was exceptionally
lower in the fourth than in the third quartile group for
baseline PC1 scores. Similarly, the annual changes in
SUVR correlated with the baseline PC1 and PC2 scores,
except for the correlation with the baseline PC1 score in
the entorhinal cortex (Fig. 4c, d).
A linear regression model that included baseline PC1
scores and demographic data (age, years of education,
sex, and presence of ApoE ε4 allele) as independent vari-
ables predicted the annual changes in the global cortical
SUVR values (R2 = 0.380, P < 0.001) better than the
model that included baseline global cortical SUVR (R2 =
0.237, P < 0.001) (Fig. 5a). The model that included both
baseline PC1 and PC2 scores had better performance
than the model that only included the PC1 score (R2 =
0.568, P < 0.001) (Fig. 5d). We established a regression
model for a training set with 39 Aβ-positive individuals
and its parameters were applied to the data of the
remaining 39 individuals in the test set. The perform-
ance of the model including baseline PC1 scores in pre-
dicting annual changes was moderate (ICC = 0.600, R2 =
0.268, P < 0.001; Fig. 5b, c). As expected, the model that
Fig. 3 Age-related changes in the PC scores and their correlation with cognitive function in 114 Aβ-positive individuals. The colors of the circles
represent individual clinical status (blue = CU, green =MCI, and red = dementia). Pearson’s correlation lines (solid), 95% confidence interval lines
(dotted), correlation coefficients (R), and P values are presented within each plot. PC, principal component; MCI, mild cognitive impairment; CU,
cognitively unimpaired; SR, standardized residuals obtained by linear regression analysis with age, years of education, sex, and presence of ApoE
ε4 allele as covariates
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Fig. 4 Annual changes in SUVR and expression of two major PCs in 78 Aβ-positive individuals who completed follow-up tau PET. Annual changes adjusted by
age, years of education, sex, presence of ApoE ε4 allele, and baseline global cortical SUVR values are presented for each quartile group of PC1 (a) and PC2
scores (b) obtained from baseline tau PET. The standard residuals for annual changes and those for the two PCs after adjusting for age, years of education, sex,
presence of ApoE ε4 allele, and baseline global cortical SUVR values are plotted in c and d. Asterisks represent a significant difference in the SUVR values
between the first and other quartile groups after correction for multiple comparisons. Error bars represent the standard error of estimated means. The colors of
the circles represent individual clinical status (blue =CU, green =MCI, and red=AD). Pearson’s correlation lines (solid), 95% confidence interval lines (dotted),
correlation coefficients (R), and P values are presented within each plot. PC, principal component; Qn, quartiles
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included both PC scores performed better than the
model that only included the PC1 scores (ICC = 0.775,
R2 = 0.456, P < 0.001; Fig. 5e, f).
Discussion
In this study, we found two major Aβ-positive AD
dementia-specific PCs of baseline tau PET. PC1 corre-
sponded to the well-known tau distribution and spread-
ing pattern while the two PC2 extremes reflected the
temporal or parietal predominance of the tau distribu-
tion. PC1 expression was more positively correlated with
the global cortical tau burden and negatively correlated
with global cognition impairment, compared with PC2
expression. Contrastingly, PC2 expression was more
negatively correlated with advancing age and visuospatial
and attention function deterioration, compared with
PC1 expression. The tau accumulation rate increased
with the increase of PC1 expression (individuals with
higher tau stage) and with the decrease of PC2
expression (individuals more with parietal predomin-
ance). A regression model that combined these two PC
scores could predict longitudinal changes in the global
cortical tau burden.
Tau pathology first appears in the transentorhinal cor-
tex, with initial spreading toward neighboring medial
temporal regions. Subsequently, it spreads to the associ-
ation neocortex and finally involves the primary cortices
[20]. This hierarchical upward spreading pattern of tau
pathology has been replicated by in vivo tau PET studies
[3, 21]. Moreover, the severity and temporal progression
of cognitive dysfunction have been reported to be closely
related to the cross-sectional tau burden and longitu-
dinal changes in tau burden measured by tau PET, re-
spectively [4–6, 22]. Therefore, tau PET is an imaging
biomarker for the AD stage and progression. In our
study, PC1 expression reflected the global tau burden;
moreover, the extent of increased 18F-flortaucipir uptake
in each PC1 quartile group reflected advanced tau
Fig. 5 Prediction of annual changes in global cortical SUVR values by baseline PC scores in 78 Aβ-positive individuals who completed follow-up
tau PET. The X-axes represent measured annual changes based on baseline and follow-up tau PET scans. Y-axes represent changes predicted by
PC1 scores (a–c) and both PC1 and PC2 scores (d–f) after adjustment for age, years of education, sex, and presence of ApoE ε4 allele. Plots for all
78 Aβ-positive individuals (a, d), 39 individuals in the training set (b, e), and 39 individuals in the test set (c, f). Linear regression lines (solid), 95%
confidence interval lines (dotted), intraclass correlation coefficient (ICC), R2, and P values are presented within each plot. PC, principal component
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stages. Additionally, the global cognition and the func-
tions of five cognitive domains worsened with advancing
PC1 expression. These findings indicate that PC1 ex-
pression could be a biomarker for the disease stage.
Notably, there was a divergent pattern in PC2 ex-
pression in individuals with a high tau burden. The
first quartile group for PC2 showed significantly in-
creased 18F-flortaucipir uptake predominantly in the
medial and lateral temporal cortices. On the other
hand, the fourth quartile group showed increased up-
take predominantly in the parietal cortex with relative
sparing of the medial temporal cortex. These two ex-
tremes of 18F-flortaucipir uptake patterns are consist-
ent with the distribution patterns of tau pathology
and volume atrophy in the typical and hippocampal-
sparing AD subtypes [23, 24]. Compared to the typ-
ical AD subtype, the hippocampal-sparing AD sub-
types, which are characterized by greater pathology
(or atrophy) in the diffuse neocortex, exhibit a youn-
ger age at onset, greater non-memory function im-
pairment, lower ApoE ε4 genotype frequency, and
faster cognitive decline [23–26]. As expected by the
age-related decrease in PC2 expression, these two ex-
tremes of uptake patterns resemble those found in
late- and early-onset AD (LOAD vs. EOAD), specific-
ally the temporal predominance pattern of tau accu-
mulation in LOAD and parietal predominance pattern
of tau accumulation in EOAD patients. Similar to the
clinical characteristics of EOAD involving more prom-
inent non-memory function than memory function
impairment [27–29], as well as worsened visuospatial
function with increased tau burden in the parieto-
occipital cortex [30], we found a negative correlation
of visuospatial and attention function with PC2 ex-
pression. Therefore, PC2 expression could be a surro-
gate marker for AD subtypes.
We previously reported that the baseline tau burden
predicted the amount of additional tau accumulation,
even in Aβ-positive individuals [6]. Similarly, in this
study, we found that baseline PC1 expression was corre-
lated with the tau accumulation rate in the global, infer-
ior parietal, and inferior temporal cortices even after
adjustment for the baseline global tau burden. There
was a tendency of increased tau accumulation rate in the
entorhinal cortex with baseline PC1 expression; how-
ever, there was an attenuated tau accumulation rate in
the entorhinal cortex in the fourth quartile group of PC1
expression. This could be explained either by possible
attenuation of active tau accumulation in regions in-
volved in early Braak’s stage or by the mixture of the in-
dividuals with parietal predominance.
Patients with the hippocampal-sparing AD subtype or
EOAD have been reported to exhibit faster progression
of cognitive impairment and volume atrophy than those
with the typical AD subtype or LOAD [23–26, 31]. In
this study, except for memory function, estimated an-
nual changes in cognitive test performances were gener-
ally greater in the fourth (parietal predominance) of PC2
expression when compared to the first (temporal pre-
dominance) quartile group. However, there was no stat-
istical difference between the quartile groups (Additional
file 1: Fig. S3). Therefore, we may expect higher tau ac-
cumulation rate in individuals with higher PC2 expres-
sion. However, contrary to our expectation, tau
accumulation rate decreased with increasing baseline
PC2 expression after adjusting for demographic variables
and baseline global tau burden. Even after only adjusting
for demographic variables, the first quartile group
showed a significantly higher tau accumulation rate in
the global cortex than the fourth quartile group.
Pathological tau protein can be transferred to distant
areas through anatomically connected networks via
prion-like cell-to-cell transmission [32–36]. In vitro or
in vivo studies have reported tau protein propagation
through the axon either by anterograde or retrograde
transport [33, 37]. However, a postmortem study sug-
gested seeding of pathological tau protein mainly
through the anterograde “top-down” connectivity by
demonstrating sequential involvement of tau pathology
within the cortical neurons from dendrites to axon [38].
Based on this theory, the parietal dominance type of tau
accumulation could be closely related to the highest
stage of disease progression and therefore has less re-
sidual potential for “top-down” transmission than the
typical temporal predominance type. The observed low
tau accumulation rate observed in individuals with par-
ietal predominance of tau accumulation could be attrib-
uted to the limited cortical area for further tau
propagation, as well as the early saturation of tau accu-
mulation in regions with a high tau burden.
Since the expression of the two PCs reflected different
baseline characteristics and longitudinal changes in tau,
we could establish a prediction model for longitudinal
tau accumulation. Despite unsatisfactory R2 and ICC
values in the test set for the model that included both
PC1 and PC2 scores for predicting the amount of add-
itional tau accumulation, this model was superior to the
model that simply included the global cortical SUVR
value or just the PCI scores.
Limitations of study
Our study was primarily limited by the lack of external
validation for replicating our findings regarding Aβ-
positive AD dementia-specific PC expressions. More-
over, there was a relatively small number of Aβ-positive
individuals who completed follow-up tau PET assess-
ments. Further, we did not enroll patients with advanced
disease.
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Conclusions
This study shows that PCA of tau PET could be useful
for obtaining image-derived biomarkers for disease pro-
gression and AD subtypes. Combining the PC expres-
sions could allow the prediction of further tau
accumulation.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13195-020-00685-4.
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mated annual changes in cognitive test performances after adjusting for
demographic variables in each quartile group of PC2 scores. Table S4.
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PC scores in 114 Aβ-positive individuals. Fig. S6. Expression of PCs cre-
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